Autoimmune estrogen dermatitis
Autoimmune progesterone dermatitis
Autosensitization dermatitis
Breast eczema (nipple eczema)
Chronic vesiculobullous hand eczema
Circumostomy eczema
Dyshidrosis (acute vesiculobullous hand eczema, cheiropompholyx, dyshidrotic eczema, pompholyx, podopompholyx)
Ear eczema
Eyelid dermatitis
Hand eczema
Hyperkeratotic hand dermatitis
Id reaction (disseminated eczema, generalized eczema)
Irritant diaper dermatitis (diaper dermatitis, napkin dermatitis)
Juvenile plantar dermatosis (atopic winter feet, dermatitis plantaris sicca, forefoot dermatitis, moon-boot foot syndrome, sweaty sock dermatitis)
Molluscum dermatitis
Nummular dermatitis (discoid eczema, microbial eczema, nummular eczema, nummular neurodermatitis)
Nutritional deficiency eczema
Sulzberger–Garbe syndrome (oid-oid disease)
Xerotic eczema (asteatotic eczema, desiccation dermatitis, eczema craquelé, pruritus hiemalis, winter eczema, winter itch)

Pustular
Pustular dermatitis is an inflammation of the skin that presents with pustular lesions. Eosinophilic pustular folliculitis (Ofujis disease, sterile eosinophilic pustulosis)
Reactive arthritis
Subcorneal pustular dermatosis (Sneddon–Wilkinson disease)

Seborrheic
Seborrheic dermatitis is a chronic, superficial, inflammatory disease characterized by scaling on an erythematous base. Infantile seborrheic dermatitis
Leiners disease
Pityriasis simplex capillitii (dandruff)
Seborrheic dermatitis (seborrheic eczema)

Disturbances of pigmentation
Disturbances of human pigmentation, either loss or reduction, may be related to loss of melanocytes or the inability of melanocytes to produce melanin or transport melanosomes correctly.
Co-administration with ketoconazole, a strong CYP3A4 inhibitor, results in a 22% increase in the AUC, and potentially an increase in the rate of adverse effects experiencedSince bedaquiline can also prolong the QT interval, use of other QT prolonging drugs should be avoided. Other medications for tuberculosis that can prolong the QT interval include fluoroquinolones and clofazimine. Mechanism of action
Bedaquiline blocks the proton pump for ATP synthase of mycobacteria. It is the first member of a new class of drugs called the diarylquinolines. Bedaquiline is bactericidal. ATP production is required for cellular energy production and its loss leads inhibition of mycobacterial growth within hours of the addition of bedaquiline. The onset of bedaquiline-induced mycobacterial cell death does not occur until several days after treatment, but nonetheless kills consistently thereafter. Resistance
The specific part of ATP synthase affected by bedaquiline is subunit c which is encoded by the gene atpE. Mutations in atpE can lead to resistance. Mutations in drug efflux pumps have also been linked to resistance. Ongoing research
In vitro experiments have indicated that Bedaquiline may also target the mitochondrial ATP synthase of malignant mammalian cells and reduce the rate of metastasis. History
Bedaquiline was described for the first time in 2004 at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting, after the drug had been in development for over seven years.